Skip to main content
TOKYO, Japan, May 31, 2016 – Hitachi High-Technologies Corporation (TOKYO: 8036, Hitachi High-Tech) announces that its wholly-owned subsidiary, Hitachi High-Technologies (Shanghai) Co., Ltd. (Hitachi High-Tech (Shanghai)) has agreed with Shanghai Nichiwa Trading Co., Ltd. (Shanghai Nichiwa) to establish a marketing and servicing joint venture in in-vitro diagnostics (IVD) analyzers and reagents in China, named Hitachi High-Tech Diagnostics (Shanghai) Ltd. (Hitachi High-Tech Diagnostics (Shanghai)) on September 1, 2016. Shanghai Nichiwa is one of Hitachi High-Tech’s major medical equipment sales agents in China.
The IVD market in China is growing in response to an increase in patients with lifestyle-related diseases as the living standards of its citizens improve, and to the government’s policy for enhancing healthcare services. Furthermore, continued growth is projected for this market as the population in China ages in step with the spread of preventive medicine. However, due to the political preference for more gradual growth under the so-called “New Normal” economy, China is in need of more efficient solutions for the delivery of clinical diagnostic testings because the healthcare system is under pressure to cut expenses at the same time.
Hitachi High-Tech Diagnostics (Shanghai), the joint venture to be established, will operate a business marketing analyzers and reagents for carrying out the blood tests crucial for conducting clinical chemistry diagnostics, as well as services providing daily support for the tests. The goal is to develop total solutions and one-stop sales and services for clinical analyzers and reagents throughout China by combining Hitachi High-Tech (Shanghai)’s long-standing capability for marketing the Group’s automated clinical chemistry analyzer systems with Shanghai Nichiwa’s accumulated business expertise for servicing the analyzers. Business alliances with major Chinese reagent manufacturers will also be examined to achieve this goal. In order to respond to customer needs for efficiency not only in clinical chemistry diagnostics but also IVD analysis in general, Hitachi High-Tech Diagnostics (Shanghai) will be directly involved, as well, in the marketing of total laboratory automation systems for improving the efficiency of clinical diagnostics.
Forming a joint venture with a Chinese company will enable Hitachi High-Tech to develop products matching the local market and promote them more efficiently in cooperation with other reagent manufacturers and sales agents in China. The Hitachi High-Tech Group will develop Hitachi High-Tech Diagnostics (Shanghai) to further enhance the solution-providing capability of its IVD business in China, and thereby contribute to the provision of efficient, high-quality healthcare to the people of China.
|Name||Hitachi High-Tech Diagnostics (Shanghai) Ltd.|
|Business||Marketing of IVD analyzers and reagents and the provision of related services in China|
|No. of employees||Approx. 100|
|Establishment||September 1, 2016 (planned)|
|Paid-in capital||Approx. US$3 million|
|Investment ratio||Hitachi High-Tech (Shanghai) 77%, Shanghai Nichiwa 23%|
|Name||Shanghai Nichiwa Trading Co., Ltd.|
|Business||Sales of IVD analyzers, among other medical equipment, and the provision of related services|
|No. of employees||Approx. 110 (group-wide)|
|Paid-in capital||RMB5 million|
Hitachi High-Technologies Corporation, headquartered in Tokyo, Japan, is engaged in activities in a broad range of fields, including Science & Medical Systems, Electronic Device Systems, Industrial Systems, and Advanced Industrial Products. The company's consolidated sales for FY 2015 were approx. ¥629 billion [USD5.7 billion]. For further information, visit http://www.hitachi-hightech.com/global/.
Hitachi High-Technologies (Shanghai) Co., Ltd., headquartered in Shanghai, China, sells and services for medical equipment, semiconductor manufacturing equipment, industrial materials, electronic materials, and industrial-use equipment. For further information, visit http://www.hitachi-hightech.com/cn/.
Aiko Matsumoto, Shota Sano
CSR & Corporate Communications Dept.,
Hitachi High-Technologies Corporation